A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

NCT05680129 on ClinicalTrials.gov · last registry update 2025-05-08

Finished 3 July 2024, after enrolling 623 people. Primary outcome, as filed: Change from baseline in HbA1c. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Sponsor type: Industry
Enrollment: 623
Started: 2023-01-10
Primary completion: 2024-07-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline in HbA1c

Conditions studied

T2DM · Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.